Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Investigational New Drugs|January 5, 2012
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumorsC Massard, R Salazar, J P Armand, et al.
European Journal of Cancer (Oxford, England : 1990)|June 23, 2009
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancersJ C Soria, C Massard, N Magné, et al.
Lung Cancer (Amsterdam, Netherlands)|July 11, 2015
Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave RoussyM Kossai, B Duchemann, C Boutros, et al.
Oral Oncology|May 10, 2024
Prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancersC Invernizzi, A Da Silva Ribeiro Mota, C Barbe, et al.
ESMO Open|August 14, 2025
Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvementI Korakis, K Ouali, B Hanvic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2011
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumorsJ-C Soria, J Cortes, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?S Postel-Vinay, Y Boursin, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abirateroneC Massard, J Mateo, Y Loriot, et al.
British Journal of Cancer|August 11, 2011
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomasF Farace, C Massard, N Vimond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2018
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancerC Massard, A Azaro, J-C Soria, et al.
Pageof 9